Germany Point-of-Care Glucose Testing Market By Product Type (Lancing Devices and Strips, Blood-Glucose Meter), By Application (Type-1 Diabetes, Type-2 Diabetes), By End User (Hospitals and Clinics, Home Care Settings, Others): Opportunity Analysis and Industry Forecast, 2023-2032

Germany Point-of-Care Glucose Testing Market

Glucose testing is an essential procedure as inappropriate glucose levels are indicator of serious medical issues. Glucose testing aids in diagnosis, prevention, and treatment of overweight or diabetes, low blood sugar, and high blood pressure. Point-of-care (PoC) glucose testing is an effective and rapid substitute to typical lab testing, with results available in less than ten minutes. The Germany point-of-care glucose testing market is projected to witness substantial traction during the forecast period in terms of revenue. Factors such as increase in awareness about pre-diabetes, unhealthy lifestyle, and surge in the elderly population are projected to surge the sales of glucose testing devices in Germany. 

Rise in diabetes incidence in Germany is a major driver of the point-of-care glucose testing market. Blood glucose level testing is one of the most essential tests performed for quick detection and management of diabetes, which is increasing demand for point-of-care glucose testing devices in the country. In addition, surge in usage of wearable glucose testing gadgets for self-monitoring blood sugar levels is anticipated to offer growth opportunities in the market. However, limited reimbursement schemes and high cost of glucose testing devices are the major factors restraining the growth of the Germany point-of-care glucose testing market. In addition, short lifespan of glucose testing equipment and shortage of experienced technicians to operate the devices hamper the market growth. Furthermore, dearth of suitable infrastructure and lack of technological understanding in rural regions are expected to impede the growth of the Germany point-of-care glucose testing market. 

The presence of several established players in the Germany point-of-care glucose testing market creates opportunities for market participants to launch innovative and technologically advanced products. Companies are investing in R&D to provide advanced products in terms of accuracy and efficiency, which is expected to increase their sales. Furthermore, boost in usage of smart glucose meters in clinics and hospitals is projected to open new market prospects. The trend of introducing new product offerings is anticipated to increase in the Germany point-of-care glucose testing market in the near future. In addition, manufacturers are expected to focus on launching products, which are cost-effective and offer advanced features to meet current customer needs. Product launches, investments, and collaborations are some of the other market strategies, which companies are projected to adopt in the market. 

The Germany point-of-care glucose testing market is segmented on the basis of product type, application, and end user. By product type the market is divided into lancing devices & strips and blood-glucose meters. According to application, the market is bifurcated into type 1 diabetes and type 2 diabetes. As per end user, the market is classified into hospitals & clinics, home care settings, and others. Rise in prevalence of diabetes in the nation is increasing the demand for point-of-care glucose testing technology. In accordance with WHO forecast, the number of diabetics in Germany are expected to reach 3.2 million by 2035, presenting considerable opportunities for the Germany point-of-care glucose testing market. 

Key market players are focusing on increasing their market presence through new product launches in the country. For instance, in March 2020, Abbott launched Freestyle Libre 2, a real time glucose monitoring system. The device offers various benefits in the form of improved precision and simplicity. In addition, the deployment of real time technology is expected to open new opportunities for industry players in the country. Product developments and partnerships are other market strategies adopted by key players in Germany point-of-care glucose testing market. For instance, in 2018, Roche Diagnostics and Novo Nordisk partnered to support the use of connected insulin pens in people with type 1 diabetes, which enables them to track and manage insulin dosage. The market players focus on leveraging technologies such as Artificial Intelligence (AI) for the development of advanced products. Pricing strategy adopted by companies in the Germany point-of-care glucose testing market is one of the key strategies for attaining profitability. The market players focus on offering cost-effective products to customers, targeting both private and public healthcare institutions. With competitive pricing, companies are able to garner a high share of the market.  

Key Benefits For Stakeholders

Enable informed decision-making process and offer market analysis based on current market situation and estimated future trends.

Analyze the key strategies adopted by major market players in Germany point-of-care glucose testing market.

Assess and rank the top factors that are expected to affect the growth of Germany point-of-care glucose testing market.

Top Player positioning provides a clear understanding of the present position of market players.

Detailed analysis of the Germany point-of-care glucose testing market segmentation assists to determine the prevailing market opportunities.

Identify key investment pockets for various offerings in the market.

Additional benefits you will get with this purchase are:

● Quarterly Update and* (only available with a corporate license, on listed price)

● 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.

● Free Upcoming Version on the Purchase of Five and Enterprise User License.

● 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)

● 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)

● Free data Pack on the Five and Enterprise User License. (Excel version of the report)

● Free Updated report if the report is 6-12 months old or older.

● 24-hour priority response*

● Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

● Product Benchmarking / Product specification and applications

○ B. Braun Melsungen A

Scope of Germany Point-of-Care Glucose Testing Market Report

1.1. Report Description

1.2. Key Market Segments

1.3. Key Benefits to the Stakeholders

1.4. Research Methodology

1.4.1. Primary Research

1.4.2. Secondary Research

1.4.3. Analyst Tools and Models

2.1. CXO Perspective

3.1. Market Definition and Scope

3.2. Key Findings

3.2.1. Top Impacting Factors

3.2.2. Top Investment Pockets

3.3. Porter’s Five Forces Analysis

3.4. Market Dynamics

3.4.1. Drivers

3.4.2. Restraints

3.4.3. Opportunities

3.5. COVID-19 Impact Analysis on the market

4.1. Overview

4.1.1. Market Size and Forecast, By Product Type

4.2. Lancing Devices and Strips

4.3. Blood-Glucose Meter

5.1. Overview

5.1.1. Market Size and Forecast, By Application

5.2. Type-1 Diabetes

5.3. Type-2 Diabetes

6.1. Overview

6.1.1. Market Size and Forecast, By End User

6.2. Hospitals and Clinics

6.3. Home Care Settings

6.4. Others

7.1. Introduction

7.2. Top winning strategies

7.3. Product Mapping of Top 10 Player

7.4. Competitive Dashboard

7.5. Competitive Heatmap

7.6. Top player positioning, 2022

8.1. Roche

8.1.1. Company overview

8.1.2. Key Executives

8.1.3. Company snapshot

8.1.4. Operating business segments

8.1.5. Product portfolio

8.1.6. Business performance

8.1.7. Key strategic moves and developments

8.2. Abbott

8.2.1. Company overview

8.2.2. Key Executives

8.2.3. Company snapshot

8.2.4. Operating business segments

8.2.5. Product portfolio

8.2.6. Business performance

8.2.7. Key strategic moves and developments

8.3. Medtronic

8.3.1. Company overview

8.3.2. Key Executives

8.3.3. Company snapshot

8.3.4. Operating business segments

8.3.5. Product portfolio

8.3.6. Business performance

8.3.7. Key strategic moves and developments

8.4. Siemens Healthineers

8.4.1. Company overview

8.4.2. Key Executives

8.4.3. Company snapshot

8.4.4. Operating business segments

8.4.5. Product portfolio

8.4.6. Business performance

8.4.7. Key strategic moves and developments

8.5. Bayer

8.5.1. Company overview

8.5.2. Key Executives

8.5.3. Company snapshot

8.5.4. Operating business segments

8.5.5. Product portfolio

8.5.6. Business performance

8.5.7. Key strategic moves and developments

8.6. Novo Nordisk

8.6.1. Company overview

8.6.2. Key Executives

8.6.3. Company snapshot

8.6.4. Operating business segments

8.6.5. Product portfolio

8.6.6. Business performance

8.6.7. Key strategic moves and developments

8.7. Pentax Medical

8.7.1. Company overview

8.7.2. Key Executives

8.7.3. Company snapshot

8.7.4. Operating business segments

8.7.5. Product portfolio

8.7.6. Business performance

8.7.7. Key strategic moves and developments

8.8. OptiMedis

8.8.1. Company overview

8.8.2. Key Executives

8.8.3. Company snapshot

8.8.4. Operating business segments

8.8.5. Product portfolio

8.8.6. Business performance

8.8.7. Key strategic moves and developments

8.9. ZEISS Group

8.9.1. Company overview

8.9.2. Key Executives

8.9.3. Company snapshot

8.9.4. Operating business segments

8.9.5. Product portfolio

8.9.6. Business performance

8.9.7. Key strategic moves and developments

8.10. B. Braun Melsungen AG

8.10.1. Company overview

8.10.2. Key Executives

8.10.3. Company snapshot

8.10.4. Operating business segments

8.10.5. Product portfolio

8.10.6. Business performance

8.10.7. Key strategic moves and development

LIST OF TABLES

TABLE 01. GERMANY POINT-OF-CARE GLUCOSE TESTING MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)

TABLE 02. GERMANY POINT-OF-CARE GLUCOSE TESTING MARKET, BY APPLICATION, 2022-2032 ($MILLION)

TABLE 03. GERMANY POINT-OF-CARE GLUCOSE TESTING MARKET, BY END USER, 2022-2032 ($MILLION)

TABLE 04. ROCHE: KEY EXECUTIVES

TABLE 05. ROCHE: COMPANY SNAPSHOT

TABLE 06. ROCHE: OPERATING SEGMENTS

TABLE 07. ROCHE: PRODUCT PORTFOLIO

TABLE 08. ROCHE: KEY STRATERGIES

TABLE 09. ABBOTT: KEY EXECUTIVES

TABLE 10. ABBOTT: COMPANY SNAPSHOT

TABLE 11. ABBOTT: OPERATING SEGMENTS

TABLE 12. ABBOTT: PRODUCT PORTFOLIO

TABLE 13. ABBOTT: KEY STRATERGIES

TABLE 14. MEDTRONIC: KEY EXECUTIVES

TABLE 15. MEDTRONIC: COMPANY SNAPSHOT

TABLE 16. MEDTRONIC: OPERATING SEGMENTS

TABLE 17. MEDTRONIC: PRODUCT PORTFOLIO

TABLE 18. MEDTRONIC: KEY STRATERGIES

TABLE 19. SIEMENS HEALTHINEERS: KEY EXECUTIVES

TABLE 20. SIEMENS HEALTHINEERS: COMPANY SNAPSHOT

TABLE 21. SIEMENS HEALTHINEERS: OPERATING SEGMENTS

TABLE 22. SIEMENS HEALTHINEERS: PRODUCT PORTFOLIO

TABLE 23. SIEMENS HEALTHINEERS: KEY STRATERGIES

TABLE 24. BAYER: KEY EXECUTIVES

TABLE 25. BAYER: COMPANY SNAPSHOT

TABLE 26. BAYER: OPERATING SEGMENTS

TABLE 27. BAYER: PRODUCT PORTFOLIO

TABLE 28. BAYER: KEY STRATERGIES

TABLE 29. NOVO NORDISK: KEY EXECUTIVES

TABLE 30. NOVO NORDISK: COMPANY SNAPSHOT

TABLE 31. NOVO NORDISK: OPERATING SEGMENTS

TABLE 32. NOVO NORDISK: PRODUCT PORTFOLIO

TABLE 33. NOVO NORDISK: KEY STRATERGIES

TABLE 34. PENTAX MEDICAL: KEY EXECUTIVES

TABLE 35. PENTAX MEDICAL: COMPANY SNAPSHOT

TABLE 36. PENTAX MEDICAL: OPERATING SEGMENTS

TABLE 37. PENTAX MEDICAL: PRODUCT PORTFOLIO

TABLE 38. PENTAX MEDICAL: KEY STRATERGIES

TABLE 39. OPTIMEDIS: KEY EXECUTIVES

TABLE 40. OPTIMEDIS: COMPANY SNAPSHOT

TABLE 41. OPTIMEDIS: OPERATING SEGMENTS

TABLE 42. OPTIMEDIS: PRODUCT PORTFOLIO

TABLE 43. OPTIMEDIS: KEY STRATERGIES

TABLE 44. ZEISS GROUP: KEY EXECUTIVES

TABLE 45. ZEISS GROUP: COMPANY SNAPSHOT

TABLE 46. ZEISS GROUP: OPERATING SEGMENTS

TABLE 47. ZEISS GROUP: PRODUCT PORTFOLIO

TABLE 48. ZEISS GROUP: KEY STRATERGIES

TABLE 49. B. BRAUN MELSUNGEN AG: KEY EXECUTIVES

TABLE 50. B. BRAUN MELSUNGEN AG: COMPANY SNAPSHOT

TABLE 51. B. BRAUN MELSUNGEN AG: OPERATING SEGMENTS

TABLE 52. B. BRAUN MELSUNGEN AG: PRODUCT PORTFOLIO

TABLE 53. B. BRAUN MELSUNGEN AG: KEY STRATERGIES LIST OF FIGURES

FIGURE 01. GERMANY POINT-OF-CARE GLUCOSE TESTING MARKET, 2022-2032

FIGURE 02. SEGMENTATION OF GERMANY POINT-OF-CARE GLUCOSE TESTING MARKET, 2022-2032

FIGURE 03. TOP INVESTMENT POCKETS IN GERMANY POINT-OF-CARE GLUCOSE TESTING MARKET (2023-2032)

FIGURE 04. PORTER FIVE-1

FIGURE 05. PORTER FIVE-2

FIGURE 06. PORTER FIVE-3

FIGURE 07. PORTER FIVE-4

FIGURE 08. PORTER FIVE-5

FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GERMANY POINT-OF-CARE GLUCOSE TESTING MARKET

FIGURE 10. GERMANY POINT-OF-CARE GLUCOSE TESTING MARKET,BY PRODUCT TYPE, 2022 ($MILLION)

FIGURE 11. GERMANY POINT-OF-CARE GLUCOSE TESTING MARKET,BY APPLICATION, 2022 ($MILLION)

FIGURE 12. GERMANY POINT-OF-CARE GLUCOSE TESTING MARKET,BY END USER, 2022 ($MILLION)

FIGURE 13. TOP WINNING STRATEGIES, BY YEAR

FIGURE 14. TOP WINNING STRATEGIES, BY DEVELOPMENT

FIGURE 15. TOP WINNING STRATEGIES, BY COMPANY

FIGURE 16. PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 17. COMPETITIVE DASHBOARD

FIGURE 18. COMPETITIVE HEATMAP: GERMANY POINT-OF-CARE GLUCOSE TESTING MARKET

FIGURE 19. TOP PLAYER POSITIONING, 2022

FIGURE 20. ROCHE: NET SALES, 2020-2022* ($MILLION)

FIGURE 21. ROCHE: REVENUE SHARE, BY SEGMENT, 2022 (%)

FIGURE 22. ROCHE: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)

FIGURE 23. ABBOTT: NET SALES, 2020-2022* ($MILLION)

FIGURE 24. ABBOTT: REVENUE SHARE, BY SEGMENT, 2022 (%)

FIGURE 25. ABBOTT: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)

FIGURE 26. MEDTRONIC: NET SALES, 2020-2022* ($MILLION)

FIGURE 27. MEDTRONIC: REVENUE SHARE, BY SEGMENT, 2022 (%)

FIGURE 28. MEDTRONIC: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)

FIGURE 29. SIEMENS HEALTHINEERS: NET SALES, 2020-2022* ($MILLION)

FIGURE 30. SIEMENS HEALTHINEERS: REVENUE SHARE, BY SEGMENT, 2022 (%)

FIGURE 31. SIEMENS HEALTHINEERS: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)

FIGURE 32. BAYER: NET SALES, 2020-2022* ($MILLION)

FIGURE 33. BAYER: REVENUE SHARE, BY SEGMENT, 2022 (%)

FIGURE 34. BAYER: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)

FIGURE 35. NOVO NORDISK: NET SALES, 2020-2022* ($MILLION)

FIGURE 36. NOVO NORDISK: REVENUE SHARE, BY SEGMENT, 2022 (%)

FIGURE 37. NOVO NORDISK: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)

FIGURE 38. PENTAX MEDICAL: NET SALES, 2020-2022* ($MILLION)

FIGURE 39. PENTAX MEDICAL: REVENUE SHARE, BY SEGMENT, 2022 (%)

FIGURE 40. PENTAX MEDICAL: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)

FIGURE 41. OPTIMEDIS: NET SALES, 2020-2022* ($MILLION)

FIGURE 42. OPTIMEDIS: REVENUE SHARE, BY SEGMENT, 2022 (%)

FIGURE 43. OPTIMEDIS: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)

FIGURE 44. ZEISS GROUP: NET SALES, 2020-2022* ($MILLION)

FIGURE 45. ZEISS GROUP: REVENUE SHARE, BY SEGMENT, 2022 (%)

FIGURE 46. ZEISS GROUP: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)

FIGURE 47. B. BRAUN MELSUNGEN AG: NET SALES, 2020-2022* ($MILLION)

FIGURE 48. B. BRAUN MELSUNGEN AG: REVENUE SHARE, BY SEGMENT, 2022 (%)

FIGURE 49. B. BRAUN MELSUNGEN AG: REVENUE SHARE, BY GEOGRAPHY, 2022 (%